# NM_004364.5(CEBPA):c.105G>A (p.Arg35=)

https://sugi.bio/variant/cebpa-p-arg35

## Summary

**CEBPA p.Arg35= (c.105G>A)** is classified **Likely benign** in CEBPA (ClinVar, Multiple submitters, 2 submitters; last evaluated 2025-07-30). Very rare (popmax 0.00843%, amr); Associated with Inborn genetic diseases.

**At a glance:** Likely benign · review: Multiple submitters · rsID rs1316909243 · 2 submitters · 2 linked conditions · very rare (popmax 0.00843%, amr)

## For patients & families {#patients}

This is a change in the CEBPA gene that is classified as likely benign — not considered disease-causing, submitted by 2 submitters, and is linked to Inborn genetic diseases.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

**Support & next steps:** [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [CEBPA](https://sugi.bio/atlas/gene/CEBPA/) |
| Protein change (HGVS p.) | p.Arg35= |
| Coding change (HGVS c.) | c.105G>A |
| MANE Select transcript | [NM_004364](https://www.ncbi.nlm.nih.gov/nuccore/NM_004364) |
| dbSNP | [rs1316909243](https://www.ncbi.nlm.nih.gov/snp/rs1316909243/) |
| Variant type | single nucleotide variant |
| Location | chr19:33302310-33302310 (GRCh38) |
| ClinVar | [VCV1105602](https://www.ncbi.nlm.nih.gov/clinvar/variation/1105602/) |

**All HGVS expressions:** `LRG_456:g.5215G>A`, `LRG_456t1:c.105G>A`, `NC_000019.10:g.33302310C>T`, `NC_000019.9:g.33793216C>T`, `NG_012022.1:g.5215G>A`, `NM_001285829.2:c.-253G>A`, `NM_001287424.2:c.210G>A`, `NM_001287435.2:c.63G>A`, `NM_004364.3:c.105G>A`, `NM_004364.5:c.105G>A`

## Computational & population evidence {#evidence}

**Concordance:** Mixed / partial computational evidence (see below).

- **Missense predictors (AlphaMissense/REVEL/SaProt) do not apply** to this variant type — they score amino-acid substitutions only. For non-missense variants the computational signal comes from conservation (below), not from a missing predictor score.
- Conservation: phyloP 2.524, GERP -2.34, phastCons 1 — highly conserved position (PP3-type support)
- CADD: **PHRED 12.45**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- SpliceAI: **not assessed** — no allele at this position is in our SpliceAI release, either because it lies outside the scored MANE transcript scope or because every allele is below Δ0.2. We cannot tell which, so this claims neither; absence is not evidence against a splicing effect.
- Population frequency (gnomAD v4.1): grpmax **0.00843%** (amr) · FAF95 0.00223% · FAF99 0.00122% · 3/35,602 in the highest group · 4/1,434,242 alleles overall — very rare (popmax 0.00843%, amr).

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| Admixed American (grpmax) | 0.00843% | 11,867 |
| European (non-Finnish) | 9.18e-05% | 1,089,628 |

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**CEBPA** population constraint: LOEUF 1.372, pLI 0.26038, missense-Z -1.2385; ClinGen dosage — haploinsufficiency 0, triplosensitivity 0 (0–3 scale). *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

Curated gene–disease validity (ClinGen):

- **acute myeloid leukemia** — Definitive (AD)

## Protein context {#protein}

Residue **35** lies in the 'required to repress e2f1:tfdp1-mediated transcription, to inhibit cell cycle and to induce adipocyte differentiation' region; the 'disordered' region.

AlphaFold model confidence (whole protein): pLDDT 63.67, 21% of residues very-high.

**2 experimental structure(s)** (PDB): [6DC0](https://www.rcsb.org/structure/6DC0), [8K8C](https://www.rcsb.org/structure/8K8C).

## What this gene does {#gene-function}

*Describes the biological roles of CEBPA (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** CEBPA's established molecular role includes transcription cis-regulatory region binding. p.Arg35= falls in the required to repress e2f1:tfdp1-mediated transcription, to inhibit cell cycle and to induce adipocyte differentiation region.


### Pathways affected {#pathways}

CEBPA participates in **4 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| [MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis](https://reactome.org/content/detail/R-HSA-9841922) | electronic |
| [Somatic hypermutation of immunoglobulin genes](https://reactome.org/content/detail/R-HSA-9938024) | electronic |
| [Transcriptional regulation of granulopoiesis](https://reactome.org/content/detail/R-HSA-9616222) | electronic |
| [Transcriptional regulation of white adipocyte differentiation](https://reactome.org/content/detail/R-HSA-381340) | electronic |

### Molecular function & processes (GO — experimentally supported) {#go}

**Molecular function:** transcription cis-regulatory region binding, RNA polymerase I transcription regulatory region sequence-specific DNA binding, DNA-binding transcription activator activity, RNA polymerase II-specific, DNA-binding transcription factor activity, kinase binding, identical protein binding.

**Biological process:** regulation of DNA-templated transcription, transcription by RNA polymerase I, negative regulation of cell population proliferation, positive regulation of transcription by RNA polymerase II, interleukin-6-mediated signaling pathway, positive regulation of DNA-templated transcription initiation.

## Clinical significance {#significance}

**Likely benign** — review status Multiple submitters *(criteria provided, multiple submitters, no conflicts)*, last evaluated 2025-07-30.

**Submitter consensus:** unanimous (2/2 Likely benign).

**Submission history:** 2 submissions (2025); classifications have been stable.

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Ambry Genetics | Likely benign | criteria provided, single submitter | clinical testing | 2025-02-14 |
| Labcorp Genetics (formerly Invitae), Labcorp | Likely benign | criteria provided, single submitter | clinical testing | 2025-07-30 |

## Associated conditions {#conditions}

[Inborn genetic diseases](https://sugi.bio/atlas/disease/inborn-genetic-diseases/), [acute myeloid leukemia](https://sugi.bio/atlas/disease/acute-myeloid-leukemia/).

**Reported phenotype names (ClinVar):** Inborn genetic diseases, Acute myeloid leukemia, Acute myeloid leukemia, adult, AML adult, Acute non-lymphocytic leukemia, Acute granulocytic leukemia, CEBPA-Associated Familial Acute Myeloid Leukemia (AML), Leukemia, acute myeloid, somatic, Leukemia, acute myelogenous, somatic.

## Similar variants {#similar}

Related CEBPA variant pages (same residue, condition, or type): [CEBPA p.Arg35Gln](/variant/cebpa-p-arg35gln), [CEBPA p.Arg35Trp](/variant/cebpa-p-arg35trp), [CEBPA p.Arg35Pro](/variant/cebpa-p-arg35pro), [CEBPA p.Arg35Gly](/variant/cebpa-p-arg35gly), [CEBPA p.Arg35fs](/variant/cebpa-p-arg35fs), [CEBPA p.Glu59Ter](/variant/cebpa-p-glu59ter), [CEBPA c.-1C>A](/variant/cebpa-c-minus-1c-a), [CEBPA c.-4C>G](/variant/cebpa-c-minus-4c-g).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-11); gnomAD v4.1 (Broad Institute, built 2026-10-06); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-07-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 1105602). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*